Genmab | GEN - Interest Expense On Debt



Genmab reported DKK9M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
Agios Pharmaceuticals 3.01M 10.05M Dec/2024
Amarin USD 3K 3K Dec/2024
Amgen USD 694M 29M Jun/2025
argenx SE 1.13M 9K Jun/2025
AstraZeneca 303M 126M Jun/2025
Bayer 495M 89M Jun/2025
BioMarin Pharmaceutical USD 2.68M 184K Jun/2025
Demant 435M 27M Jun/2025
Exelixis 23.4M 3.9M Sep/2023
Fresenius Medical Care EUR 96.58M 15.58M Jun/2025
Galapagos EUR 780K 49.34M Mar/2025
Genmab DKK 9M 4M Jun/2025
GlaxoSmithKline 184M 22M Jun/2025
GN Store Nord 297M 69M Jun/2025
GRIFOLS EUR 202.71M 94.07M Jun/2024
Hikma Pharmaceutical 22M 9M Jun/2024
Insmed USD 21.24M 1.5M Jun/2025
Lonza CHF 70M 11M Dec/2024
Merck 79M 1000K Jun/2025
Novartis USD 289M 19M Jun/2025
Regeneron Pharmaceuticals USD 3.6M 5.1M Jun/2025
Roche Holding CHF 311.5M 1000K Dec/2024
Sanofi 148M 65M Jun/2025
UCB 108M 16M Dec/2024